ROR1s, roar twice: ADC pro Siegall takes on tricky target at Immunome Feb. 7, 2024 By Randy Osborne Immunome Inc. gained renewed attention for its pipeline by way of the Feb. 6 deal to buy from Ayala Pharmaceuticals Inc. the phase III-stage small-molecule gamma secretase inhibitor AL-102 (plus related drug candidate AL-101).Read More
